Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Clinics (Sao Paulo) ; 79: 100346, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38574572

RESUMO

BACKGROUND AND OBJECTIVE: Lower limb varicose veins are a prevalent disease associated with several available treatment options, including conventional surgery and polidocanol foam sclerotherapy. However, few studies have analyzed therapeutic modality outcomes based on Patient-Reported Outcome Measures (PROMs). This large sample-size study was designed to evaluate the outcomes of polidocanol foam sclerotherapy compared to conventional surgery based on an analysis of PROMs. METHODS: This was a prospective, observational, and qualitative study of 205 patients who underwent varicose vein treatment with either polidocanol foam sclerotherapy (57 patients, 90 legs) or conventional surgery (148 patients, 236 legs). Patients were preoperatively assessed and re-evaluated 30 days after the procedure using the Venous Disease Severity Score (VCSS) and specific venous disease quality-of-life questionnaires (VEINES-QoL/Sym). RESULTS: Both treatments significantly improved VCSS and VEINES results 30 days after the procedure (p < 0.05). However, surgery promoted greater improvements in VCSS (on average 4.02-points improvement, p < 0.001), VEINES-QoL (average 8-points improvement, p < 0.001), and VEINES-Sym (average 11.66 points improvement, p < 0.001) than did sclerotherapy. Postoperative pain and aesthetic concerns about the legs were the domains of the questionnaires in which the results varied the most between the treatment modalities, with worse results for sclerotherapy. CONCLUSION: Both polidocanol foam sclerotherapy and conventional surgery positively impact patients' quality of life after 30 days, but the improvement is more significant for patients who undergo conventional surgery.


Assuntos
Qualidade de Vida , Varizes , Humanos , Polidocanol , Polietilenoglicóis , Estudos Prospectivos , Veia Safena , Soluções Esclerosantes/uso terapêutico , Soluções Esclerosantes/efeitos adversos , Escleroterapia/efeitos adversos , Resultado do Tratamento , Varizes/cirurgia , Varizes/terapia
2.
Clinics ; Clinics;79: 100346, 2024. tab
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1557583

RESUMO

Abstract Background and objective: Lower limb varicose veins are a prevalent disease associated with several available treatment options, including conventional surgery and polidocanol foam sclerotherapy. However, few studies have analyzed therapeutic modality outcomes based on Patient-Reported Outcome Measures (PROMs). This large sample-size study was designed to evaluate the outcomes of polidocanol foam sclerotherapy compared to conventional surgery based on an analysis of PROMs. Methods: This was a prospective, observational, and qualitative study of 205 patients who underwent varicose vein treatment with either polidocanol foam sclerotherapy (57 patients, 90 legs) or conventional surgery (148 patients, 236 legs). Patients were preoperatively assessed and re-evaluated 30 days after the procedure using the Venous Disease Severity Score (VCSS) and specific venous disease quality-of-life questionnaires (VEINES-QoL/Sym). Results: Both treatments significantly improved VCSS and VEINES results 30 days after the procedure (p < 0.05). However, surgery promoted greater improvements in VCSS (on average 4.02-points improvement, p < 0.001), VEINES-QoL (average 8-points improvement, p < 0.001), and VEINES-Sym (average 11.66 points improvement, p < 0.001) than did sclerotherapy. Postoperative pain and aesthetic concerns about the legs were the domains of the questionnaires in which the results varied the most between the treatment modalities, with worse results for sclerotherapy. Conclusion: Both polidocanol foam sclerotherapy and conventional surgery positively impact patients' quality of life after 30 days, but the improvement is more significant for patients who undergo conventional surgery.

3.
Int J Angiol ; 32(3): 172-178, 2023 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-37576530

RESUMO

Chronic venous disease (CVD) associated with great saphenous vein (GSV) reflux has a higher prevalence of pain in the lower limbs. This study evaluates the impact of ultrasound-guided foam sclerotherapy (UGFS) for GSV and symptom control, accessed by the visual analogue scale (VAS). Patients with CVD who underwent GSV-UGFS were included in this retrospective cohort (417 limbs). The pain was measured before and after the treatment. The scale alteration was assessed as a function of age, sex, Clinical Etiologic Anatomic Pathophysiologic (CEAP) classes, total of sclerotherapy sessions, GSV occlusion patterns, and ulcer healing. Majority of patients were female (59.2%), and the mean age was 56 ± 11.5 years. In the total sample, 78.2% of the GSVs were fully occluded, 19.7% had partial occlusion, 2.2% remained open, and 3.2 ± 1.9 (median = 3.0) sessions were performed. The reduction of symptoms occurred in 88.3% of participants (VAS drop median = 4.8). Patients younger than 50 years and females had the greatest VAS decreases. When comparing the outcomes of complete occlusion versus partial occlusion, there was no significant difference in VAS pain reduction ( p = 0.14). The comparison between CEAP clinical classes also did not show statistically significant differences in delta VAS ( p = 0.71). GSV-UGFS was effective for pain control. However, this improvement does not appear to be related to the pattern of occlusion, indicating that in the short term, the outcomes of total and partial occlusion suggest successful management of symptoms. Other aspects such as gender, age, pretreatment pain intensity, and CEAP classes seem to play a role in the clinical outcome.

4.
Acta ortop. mex ; 35(6): 529-533, nov.-dic. 2021. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1403073

RESUMO

Resumen: Introducción: El quiste óseo aneurismático es un raro tumor osteolítico benigno, pero agresivo para el que aún no existe tratamiento ideal. Los comunicados sobre tratamiento mediante escleroterapia en población pediátrica son escasos y en nuestra región más aún. El objetivo es comunicar la experiencia del tratamiento del quiste óseo aneurismático con polidocanol 3%. Material y métodos: Estudio retrospectivo, descriptivo y transversal. Período: Junio de 2017 a Junio de 2021. Inclusión: pacientes con diagnóstico histológico de quiste óseo aneurismático. Bajo anestesia general y guía fluoroscópica se realizó punción intralesional con aguja 16G a través de la cual se administró lentamente el polidocanol 3%. Datos: historia clínica. Las variables cuantitativas se expresarán en medidas de tendencia central y de dispersión; las variables cualitativas se expresarán como frecuencias o porcentajes. Resultados: Se incluyeron nueve pacientes consecutivos, todos presentaban dolor y tumoración en alguna de las extremidades. Género: tres femeninos y seis masculinos. Edad: mediana 10.5 años (rango: 2-15.1). Peso: mediana 32.8 kg (rango: 11-44.5). Total de procedimientos: 44, procedimientos por paciente: promedio 4.9 (DE: ± 2.0). Tiempo de procedimiento: promedio 33.9 minutos (DE: ± 18.3); radiación: promedio 1.34 mGy (DE: ± 1.55). Hospitalización: un día, excepto un paciente. Complicaciones: Daño de piel en un caso, no recidivas. Seguimiento: de 12 a 50 meses. Conclusión: En esta serie pediátrica el polidocanol 3% fue útil y efectivo para el tratamiento del quiste óseo aneurismático con escasas complicaciones. Una desventaja es que requiere varias sesiones y además, no se ha demostrado una diferencia significativa entre otras formas de tratamiento en términos de la tasa de recurrencia.


Abstract: Introduction: The aneurysmal bone cyst is a rare benign but aggressive osteolytic tumor for which there is still no ideal treatment, the reports on treatment by sclerotherapy in the pediatric population are scarce and in our region even less. The objective is to communicate the experience of the treatment of aneurysmal bone cyst with polydocanol 3%. Material and methods: Retrospective, descriptive and cross-sectional study. Period: June/2017 to June/2021. Inclusion: patients with histological diagnosis of aneurysmal bone cyst; Under general anesthesia and fluoroscopic guidance, intralesional puncture with 16G needle was performed through which 3% polydocanol was slowly administered. Data: medical history. Quantitative variables shall be expressed in measures of central tendency and dispersion; qualitative variables shall be expressed as frequencies or percentages. Results: Nine consecutive patients were included, all of whom had pain and tumor in one of the extremities. Gender: 3 female and 6 male. Age: median 10.5 years (range: 2-15.1). Weight: median 32.8 kg (range: 11-44.5). Total procedures: 44; procedures per patient: mean 4.9 (SD: ± 2.0). Procedure time: mean 33.9 minutes (SD: ± 18.3); radiation: mean 1.34 mGy (SD: ± 1.55). Hospitalization: one day, except one patient. Complications: skin damage in one case, no recurrences follow-up: 12 to 50 months. Conclusion: In this pediatric series, polydocanol 3% was useful and effective for the treatment of aneurysmal bone cyst, with few complications. One disadvantage is that it requires several sessions and in addition, no significant difference has been demonstrated between other forms of treatment in terms of the recurrence rate.

5.
Acta Ortop Mex ; 35(6): 529-533, 2021.
Artigo em Espanhol | MEDLINE | ID: mdl-35793253

RESUMO

INTRODUCTION: The aneurysmal bone cyst is a rare benign but aggressive osteolytic tumor for which there is still no ideal treatment, the reports on treatment by sclerotherapy in the pediatric population are scarce and in our region even less. The objective is to communicate the experience of the treatment of aneurysmal bone cyst with polydocanol 3%. MATERIAL Y METHODS: Retrospective, descriptive and cross-sectional study. Period: June/2017 to June/2021. Inclusion: patients with histological diagnosis of aneurysmal bone cyst; Under general anesthesia and fluoroscopic guidance, intralesional puncture with 16G needle was performed through which 3% polydocanol was slowly administered. Data: medical history. Quantitative variables shall be expressed in measures of central tendency and dispersion; qualitative variables shall be expressed as frequencies or percentages. RESULTS: Nine consecutive patients were included, all of whom had pain and tumor in one of the extremities. Gender: 3 female and 6 male. Age: median 10.5 years (range: 2-15.1). Weight: median 32.8 kg (range: 11-44.5). Total procedures: 44; procedures per patient: mean 4.9 (SD: ± 2.0). Procedure time: mean 33.9 minutes (SD: ± 18.3); radiation: mean 1.34 mGy (SD: ± 1.55). Hospitalization: one day, except one patient. Complications: skin damage in one case, no recurrences follow-up: 12 to 50 months. CONCLUSION: In this pediatric series, polydocanol 3% was useful and effective for the treatment of aneurysmal bone cyst, with few complications. One disadvantage is that it requires several sessions and in addition, no significant difference has been demonstrated between other forms of treatment in terms of the recurrence rate.


INTRODUCCIÓN: El quiste óseo aneurismático es un raro tumor osteolítico benigno, pero agresivo para el que aún no existe tratamiento ideal. Los comunicados sobre tratamiento mediante escleroterapia en población pediátrica son escasos y en nuestra región más aún. El objetivo es comunicar la experiencia del tratamiento del quiste óseo aneurismático con polidocanol 3%. MATERIAL Y MÉTODOS: Estudio retrospectivo, descriptivo y transversal. Período: Junio de 2017 a Junio de 2021. Inclusión: pacientes con diagnóstico histológico de quiste óseo aneurismático. Bajo anestesia general y guía fluoroscópica se realizó punción intralesional con aguja 16G a través de la cual se administró lentamente el polidocanol 3%. Datos: historia clínica. Las variables cuantitativas se expresarán en medidas de tendencia central y de dispersión; las variables cualitativas se expresarán como frecuencias o porcentajes. RESULTADOS: Se incluyeron nueve pacientes consecutivos, todos presentaban dolor y tumoración en alguna de las extremidades. Género: tres femeninos y seis masculinos. Edad: mediana 10.5 años (rango: 2-15.1). Peso: mediana 32.8 kg (rango: 11-44.5). Total de procedimientos: 44, procedimientos por paciente: promedio 4.9 (DE: ± 2.0). Tiempo de procedimiento: promedio 33.9 minutos (DE: ± 18.3); radiación: promedio 1.34 mGy (DE: ± 1.55). Hospitalización: un día, excepto un paciente. Complicaciones: Daño de piel en un caso, no recidivas. Seguimiento: de 12 a 50 meses. CONCLUSIÓN: En esta serie pediátrica el polidocanol 3% fue útil y efectivo para el tratamiento del quiste óseo aneurismático con escasas complicaciones. Una desventaja es que requiere varias sesiones y además, no se ha demostrado una diferencia significativa entre otras formas de tratamiento en términos de la tasa de recurrencia.


Assuntos
Cistos Ósseos Aneurismáticos , Adolescente , Cistos Ósseos Aneurismáticos/diagnóstico , Cistos Ósseos Aneurismáticos/terapia , Criança , Pré-Escolar , Estudos Transversais , Feminino , Humanos , Masculino , Uso Off-Label , Polidocanol/uso terapêutico , Estudos Retrospectivos
6.
J Vasc Surg Venous Lymphat Disord ; 9(1): 154-162, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-32739509

RESUMO

OBJECTIVE: Sclerotherapy for the treatment of varicose veins is one of the most common medical procedures performed in the Western world, and hyperpigmentation is one of the most frequent, dreaded, minor adverse events. There has recently been some interest in investigating the inflammatory response of the local endothelium after sclerotherapy and the possible benefits of venoactive drugs because of their pleiotropic properties. The aim of this study was to evaluate whether adding a venoactive drug (sulodexide) to the standard sclerotherapy treatment protocol for patients with varicose veins can reduce the occurrence of postsclerotherapy hyperpigmentation. METHODS: We carried out a prospective, multicenter, randomized controlled trial with a parallel group design. It included 720 patients with telangiectasia, reticular veins, or varicose veins who were candidates for sclerotherapy. Patients with reflux in deep system or saphenous veins were excluded. Group A consisted of 354 patients who received an oral dose of sulodexide twice a day for 7 days before scheduled sclerotherapy; the treatment then continued for 3 months. Group B consisted of 366 patients who received the standard sclerotherapy protocol. Polidocanol was used as the sclerosing agent, and 20 to 30 mm Hg compression stockings were used in both groups for 7 days. Control photographs were taken, and a follow-up examination took place after 1 month and 3 months. Computer software was used to analyze the treated area for incidence of hyperpigmentation, total area of hyperpigmentation, skin tone increase in the hyperpigmented area, vein disappearance, and incidence of major bleeding. The sample size was calculated to give a statistical power of 80%. Student t-test and the χ2 test were used for comparative analyses, as appropriate. The level of significance was set at P < .05. RESULTS: A total of 609 patients completed the 3-month follow-up: 312 in group A and 297 in group B. After 1 month, the incidence of hyperpigmentation was 8.7% in group A and 14.8% in group B (P = .01). Group A developed an average area of hyperpigmentation of 10.7% compared with 18.2% in group B (P = .01), and the skin tone of the hyperpigmented area was lower in group A than in group B (P = .02). However, the latter difference was not significant after 3 months. The overall vein disappearance rate was similar in both groups. CONCLUSIONS: Our analysis shows that by adding a venoactive drug (sulodexide) to the standard sclerotherapy protocol, the occurrence of hyperpigmentation is reduced without affecting the desired therapeutic vein elimination response.


Assuntos
Glicosaminoglicanos/uso terapêutico , Hiperpigmentação/prevenção & controle , Polidocanol/efeitos adversos , Soluções Esclerosantes/efeitos adversos , Escleroterapia/efeitos adversos , Pigmentação da Pele/efeitos dos fármacos , Telangiectasia/terapia , Varizes/terapia , Adulto , Feminino , Glicosaminoglicanos/efeitos adversos , Humanos , Hiperpigmentação/diagnóstico , Hiperpigmentação/etiologia , Masculino , México , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de Tempo , Resultado do Tratamento
7.
J. Vasc. Bras. (Online) ; J. vasc. bras;19: e20190112, 2020. graf
Artigo em Português | LILACS | ID: biblio-1056670

RESUMO

Resumo A formação de linfocele, resultante da transecção dos canais linfáticos durante procedimentos cirúrgicos ou traumas, é relativamente comum, sendo relatada em aproximadamente 30% dos pós-operatórios de ressecção de linfonodos. Ela pode evoluir assintomática ou pode apresentar complicações, como dor, infecção secundária, compressão de vasos sanguíneos, a qual evolui para estase, trombose e edema. Seu tratamento ainda é de difícil consenso. Este artigo propõe descrever três casos em que o tratamento foi realizado a partir de ecoescleroterapia com polidocanol. Sua relevância está na escassez de relatos na literatura.


Abstract Formation of lymphocele secondary to transection of lymphatic channels during surgical procedures or traumas is relatively common and is reported in the postoperative period of approximately 30% of lymph node resection procedures. The condition may be asymptomatic or can present with complications such as pain, secondary infection, and compression of blood vessels, which can cause stasis, thrombosis, and edema. There is no consensus on treatment. This article describes three cases in which treatment was provided using polidocanol echosclerotherapy. Its relevance lies in the scarcity of reports in the literature.


Assuntos
Humanos , Feminino , Adulto , Pessoa de Meia-Idade , Idoso de 80 Anos ou mais , Linfocele/terapia , Escleroterapia/métodos , Polidocanol/uso terapêutico , Período Pós-Operatório , Escleroterapia/instrumentação , Vasos Linfáticos/lesões , Edema
8.
Paraguay Oral Research ; 8(1): 47-54, julio 2019.
Artigo em Espanhol | BDNPAR, LILACS | ID: biblio-1021725

RESUMO

El hemangioma, según la Organización Mundial de la Salud (OMS), es una neoplasia vascular benigna, caracterizada por la proliferación anormal de vasos sanguíneos, se presenta como una lesión única, pudiéndose observar en cualquier parte del organismo, sin embargo es más incidente en el área de cabeza y cuello, con predominio en los labios, en la lengua y en la mucosa yugal. Técnicamente, su exrpación quirúrgica es dicil y desafiante, al estar cargada con complicaciones como hemorragia, escisión incompleta, desfiguración facial y recurrencia. Objevo: relatar el caso clínico de un paciente con hemangioma lingual tratado con Polidocanol al 0,5%. Se necesitaron de 4 sesiones de aplicación del agente esclerosaste para que retrocediera completamente la lesión donde en cada infiltración se ulizó 1ml y en la úlma sesión 0.7 ml, logrando en esta úlma obtener la desaparición de la lesión por lo que el pronósco fue bueno. Conclusión: De acuerdo a los resultados de este trabajo el uso del Polidocanol al 0.5% en tratamientos de hemangioma linguales resulta ser una técnica bastante efecva, ya que con su prácca nos da una disminución del volumen de dicha lesión


The hemangioma, according to theWorldHealthOrganizaon (WHO), is a benign vascular neoplasm, characterized by the abnormal proliferaon of blood vessels, it presents as a single lesion, it can be found anywhere in the body, however it is more incident in thearea of the head and neck, predominantlyonthelips, onthetongue and onthejugal mucosa. Technically, its surgical removal is difficult and challenging, incomplete disease, facial disfigurement and recurrence. Objecve: to report the clinical case of a paentwith lingual hemangioma treatedwith 0.5% Polidocanol. iook 4 sessions of applicaon of thesclerosingagent to completelyretrachelesionwhere 1 ml wasused in eachinfiltraon and 0.7 ml in thelastsession, obtainingthedisappear of thelesion in thelaer, so the prognosis wasgood. Conclusion: According to the results of this study, the use of Polidocanol at 0.5% in lingual hemangioma treatmentsis a very effecve technique, and with its pracce we have a decrease in the volume of this lesion


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Soluções Esclerosantes/uso terapêutico , Neoplasias da Língua/tratamento farmacológico , Polidocanol/uso terapêutico , Hemangioma/tratamento farmacológico , Soluções Esclerosantes/administração & dosagem , Polidocanol/administração & dosagem
9.
J Vasc Bras ; 19: e20190112, 2019 Dec 12.
Artigo em Inglês | MEDLINE | ID: mdl-31921320

RESUMO

Formation of lymphocele secondary to transection of lymphatic channels during surgical procedures or traumas is relatively common and is reported in the postoperative period of approximately 30% of lymph node resection procedures. The condition may be asymptomatic or can present with complications such as pain, secondary infection, and compression of blood vessels, which can cause stasis, thrombosis, and edema. There is no consensus on treatment. This article describes three cases in which treatment was provided using polidocanol echosclerotherapy. Its relevance lies in the scarcity of reports in the literature.

10.
An. Fac. Cienc. Méd. (Asunción) ; 51(2): 69-78, may-ago. 2018.
Artigo em Espanhol | LILACS | ID: biblio-946475

RESUMO

Introducción: La esclerosis se caracteriza por la destrucción celular epitelial con apoptosis, inflamación estéril, fibrosis irreversible y disminución de la masa tisular por retracción con subsecuente obliteración de la luz de los quistes y/o vasos sanguíneos. Existen diferentes sustancias esclerosantes que pueden ser utilizados. Aun así, actualmente no se han definido pautas claras en el manejo con sustancias esclerosantes. Esto puede considerarse como un tratamiento poco invasivo y efectivo. Objetivo: Determinar la eficacia y seguridad del polidocanol versus alcohol absoluto como sustancias esclerosantes en modelo experimental animal. Materiales y Métodos: El estudio se realizó con 34 ratas, distribuidas en forma aleatoria en 3 grupos. Grupo A con 16 ratas a las cuales se les introdujo 1 ml de polidocanol intravesical. Grupo B con 16 ratas a las que se les introdujo 1 ml de alcohol absoluto intravesical. Grupo C (control) con 2 ratas sin intervención. Las 2 ratas del grupo control fueron sacrificadas con sobredosis de halotano. Igualmente las ratas de cada grupo experimental, que fueron sacrificadas en pares, escogidos al azar, a las 12, 24, 48, 72, 96 y 120 horas post aplicación respectivamente. Luego se realizó el estudio anatomopatológico. Se verificó la profundidad y extensión de la esclerosis y se adjudicó puntaje según escala numérica previamente diseñada. Se determinó y comparó la eficacia y seguridad de ambas sustancias dependiendo de la extensión y profundidad de la esclerosis según el tiempo de acción con regresión logística y test exacto de Fisher. Resultados: Ambas sustancias mostraron similar efectividad al producir esclerosis con retracción de la pared vesical en 100% de los casos después de 24 horas de aplicación. El polidocanol mostró acción biológica progresiva encontrándose correlación entre el tiempo de acción y la profundidad de la esclerosis mediante el análisis de regresión logística con coeficiente de correlación de 0.75 e índice de probabilidad: 0.00183 (p < 0.05). El alcohol absoluto produjo esclerosis profunda inmediata, sin correlación con el tiempo de acción, con coeficiente de correlación de - 0.0465 con un índice de probabilidad de 0.864 (p > 0.05). Se estimó la seguridad de las sustancias según el hallazgo de esclerosis transmural y lesión de órganos vecinos. En ningún caso con polidocanol (0%) hubo paso transmural ni lesión de órganos vecinos mientras que en 83,33% de los casos del alcohol absoluto se presentó esclerosis transmural con lesión de órganos adyacentes en 50% de los casos (Test de Fisher's p < 0.0001 extremadamente significativo). Ninguna de las 2 sustancias produjo lesiones de órganos a distancia. Conclusiones: Tanto el alcohol como el polidocanol son efectivos para generar esclerosis. La esclerosis con polidocanol impresiona ser segura por quedar limitada a la vejiga. La escleroterapia con alcohol no parece ser segura porque genera esclerosis transmural y lesión de órganos contiguos. La diseminación de las sustancias a través de vasos sanguíneos o linfáticos con lesiones de órganos distantes no ocurrió en ningún caso y parece improbable ya que los esclerosantes producen la oclusión de estos vasos.


Introduction: Sclerosis is characterized by epithelial cell destruction with apoptosis, sterile inflammation, irreversible fibrosis and decreased tissue mass by retraction with subsequent obliteration of the lumen of the cysts and / or blood vessels. There are different sclerosing substances that can be used. Even so, clear guidelines have not yet been defined in the management of sclerosing substances. This can be considered as a minimally invasive and effective treatment. Objective: To determine the efficacy and safety of polidocanol versus absolute alcohol as sclerosing substances in an experimental model. Materials and Methods: The study was conducted with 34 rats, randomly distributed in 3 groups. Group A with 16 rats to which 1 ml of intravesical polidocanol was introduced. Group B with 16 rats to which 1 ml of intravesical absolute alcohol was introduced. Group C (control) with 2 rats without intervention. The 2 rats of the control group were sacrificed with halothane overdose. Also the rats of each experimental group, which were sacrificed in pairs, chosen at random, at 12, 24, 48, 72, 96 and 120 hours after application respectively. Then the anatomopathological study was carried out. The depth and extension of the sclerosis was verified and a score was awarded according to a previously designed numerical scale. The efficacy and safety of both substances were determined and compared depending on the extension and depth of the sclerosis according to the time of action with logistic regression and Fisher's exact test. Results: Both substances showed similar effectiveness in producing sclerosis with retraction of the bladder wall in 100% of the cases after 24 hours of application. The polidocanol showed progressive biological action, finding a correlation between the time of action and the depth of the sclerosis by means of the logistic regression analysis with a correlation coefficient of 0.75 and a probability index of 0.00183 (p <0.05). Absolute alcohol produced immediate deep sclerosis, without correlation with the time of action, with a correlation coefficient of - 0.0465 with a probability index of 0.864 (p> 0.05). The safety of the substances was estimated according to the finding of transmural sclerosis and injury to close organs. In no case with polidocanol (0%) there was transmural passage or injury of close organs, while in 83.33% of cases of absolute alcohol, transmural sclerosis with lesion of adjacent organs occurred in 50% of the cases (Fisher's Test p <0.0001 extremely significant). None of the 2 substances produced remote organ injuries. Conclusions: Both alcohol and polidocanol are effective in generating sclerosis. Sclerosis with polidocanol is safe because it is limited to the bladder. Sclerotherapy with alcohol does not appear to be safe because it generates transmural sclerosis and injury to contiguous organs. The dissemination of the substances through blood or lymphatic vessels with lesions of distant organs did not occur in any case and seems unlikely since the sclerosants produce the occlusion of these vessels

11.
Taiwan J Obstet Gynecol ; 55(5): 654-658, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27751411

RESUMO

OBJECTIVE: Placenta accreta is one of the main obstetrical complications worldwide. The aim of this study was to report the experience of managing placenta accreta with a 6% polidocanol solution sclerotherapy. MATERIALS AND METHODS: We selected patients between 37 weeks of gestation and 38 weeks of gestation, diagnosed with placenta accreta, treated at the Maternal Perinatal Hospital "Monica Pretelini Sáenz", Toluca, Mexico, during the period from November 2013 to August 2014. The surgical technique has two steps: (1) fundic-arciform caesarean section followed by a 6% polidocanol sclerosing solution through a 6Fr neonatal feeding tube upon its reaching the placental bed; (2) total abdominal hysterectomy with internal hypogastric artery ligation. RESULTS: Data were collected from 11 patients with a mean age of 33.9 years (range, 26-42 years) and 2.8±0.6 days of hospitalization in the obstetrical intensive care unit. The majority of patients were classified as having pregnancies at an advanced age. All women were multigravidas. Bleeding volume exhibited a range between 2.5 L and 3 L without any case of neonatal death but one mother died because of coagulopathy. CONCLUSION: We conclude that the technique that we are reporting is feasible for implementation in obstetric hospitals, with technical and economic feasibility.


Assuntos
Placenta Acreta/terapia , Polietilenoglicóis/administração & dosagem , Escleroterapia/métodos , Adulto , Relação Dose-Resposta a Droga , Feminino , Seguimentos , Humanos , Recém-Nascido , Polidocanol , Gravidez , Resultado da Gravidez , Estudos Prospectivos , Soluções Esclerosantes/administração & dosagem
12.
Phlebology ; 28(8): 441-4, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23188814

RESUMO

OBJECTIVE: To assess the presence of pulmonary embolism and inflammation after polidocanol foam injection into the peripheral veins of rabbits. METHOD: The animals were treated with polidocanol foam (1 or 3 mg/kg) or vehicle. Early (15 minutes) and late (30 days) animals were evaluated by perfusional lung scintigraphy and histopathological examination. RESULTS: In the control group no alterations were found. After polidocanol foam injection it was observed that an important reduction of pulmonary perfusion in the early periods, was mainly in the left lung (P < 0.001), with consequent embolism in the histological evaluation. In late periods it was observed that the presence of thrombus was with fibrin in small veins, compatible with chronic thrombus and the presence of chronic pulmonary inflammation. CONCLUSIONS: The injection of polidocanol foam in experimental animals can induce venous embolism and chronic inflammatory infiltration.


Assuntos
Pulmão/irrigação sanguínea , Pulmão/patologia , Polietilenoglicóis/efeitos adversos , Embolia Pulmonar/induzido quimicamente , Embolia Pulmonar/patologia , Soluções Esclerosantes/efeitos adversos , Doença Aguda , Animais , Doença Crônica , Feminino , Masculino , Polidocanol , Polietilenoglicóis/farmacologia , Coelhos , Soluções Esclerosantes/farmacologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA